FBR-002 is under clinical development by Fab’entech and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FBR-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FBR-002 overview

FBR-002 are under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are administered by the intravenous route as a solution. The drug candidates are being developed based on Fab’entech platform.

Fab’entech overview

Fab’entech (Fabentech) specializes in the development and production of emergency treatments aimed at combating the risks associated with bioterrorism and emerging infectious diseases that are considered priorities for public health. The company’s major products developed by Fabentech include FabenFLU for H5N1 avian influenza and FabenCOV for COVID-19 treatment, alongside antidotes for plant-based toxins identified as biothreats. Its products are designed for use in medical countermeasures during health crises, serving governments, health organizations, and the military in their efforts to prepare for and respond to public health emergencies. Fab’entech works in partnership with Sanofi Pasteur, Centre International de Recherche en Infectiologie, LyonBiopole, the US Army Medical Research Institute of Infectious Diseases. The company offers its products through distributors across France. Fab’entech is headquartered in Lyon, Auvergne, France.

For a complete picture of FBR-002’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.